Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
+9.61%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$43.5B
AUM Growth
+$8.16B
(+23%)
Cap. Flow
+$3.86B
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
11.55%
Holding
3,919
New
249
Increased
1,063
Reduced
1,013
Closed
119
Top Buys
| 1 |
Kenvue
KVUE
|
$439M |
| 2 |
AT&T
T
|
$437M |
| 3 |
Cummins
CMI
|
$427M |
| 4 |
Bunge Global
BG
|
$340M |
| 5 |
DaVita
DVA
|
$232M |
Top Sells
| 1 |
Qualcomm
QCOM
|
$453M |
| 2 |
AbbVie
ABBV
|
$447M |
| 3 |
Phillips 66
PSX
|
$441M |
| 4 |
D.R. Horton
DHI
|
$440M |
| 5 |
Booking.com
BKNG
|
$405M |
Sector Composition
| 1 | Consumer Discretionary | 17.42% |
| 2 | Energy | 16.95% |
| 3 | Industrials | 11.93% |
| 4 | Technology | 11.17% |
| 5 | Healthcare | 10.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Beam Therapeutics
BEAM
$2.11B
| $37.5K | ﹤0.01% |
+1,134
| New | +$37.5K |
|
1302
Novavax
NVAX
$1.28B
| $37.4K | ﹤0.01% |
+7,828
| New | +$37.4K |
|
1303
Celldex Therapeutics
CLDX
$1.52B
| $37.4K | ﹤0.01% |
+890
| New | +$37.4K |
|
1304
Protolabs
PRLB
$1.19B
| $37.3K | ﹤0.01% |
1,044
| – | – |
|
1305
BioCryst Pharmaceuticals
BCRX
$1.74B
| $37.1K | ﹤0.01% |
+7,306
| New | +$37.1K |
|
1306
Keros Therapeutics
KROS
$633M
| $37.1K | ﹤0.01% |
+560
| New | +$37.1K |
|
1307
Geron
GERN
$893M
| $37K | ﹤0.01% |
+11,223
| New | +$37K |
|
1308
CRISPR Therapeutics
CRSP
$4.99B
| $36.7K | ﹤0.01% |
+538
| New | +$36.7K |
|
1309
Cohu
COHU
$950M
| $36.4K | ﹤0.01% |
1,093
-749,946
| -100% | -$25M |
|
|
MORF
1310
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $36.3K | ﹤0.01% |
+1,030
| New | +$36.3K |
|
1311
Progress Software
PRGS
$1.88B
| $36.2K | ﹤0.01% |
679
+306
| +82% | +$16.3K |
|
1312
Energizer
ENR
$1.96B
| $36.2K | ﹤0.01% |
1,228
+415
| +51% | +$12.2K |
|
1313
Catalyst Pharmaceutical
CPRX
$2.48B
| $36.1K | ﹤0.01% |
+2,265
| New | +$36.1K |
|
1314
Ardelyx
ARDX
$1.57B
| $35.8K | ﹤0.01% |
+4,909
| New | +$35.8K |
|
1315
Vera Therapeutics
VERA
$1.54B
| $34.9K | ﹤0.01% |
+810
| New | +$34.9K |
|
1316
Prothena Corp
PRTA
$460M
| $34.9K | ﹤0.01% |
+1,410
| New | +$34.9K |
|
1317
Calix
CALX
$3.96B
| $34.8K | ﹤0.01% |
1,050
-8,041
| -88% | -$267K |
|
1318
Amphastar Pharmaceuticals
AMPH
$1.37B
| $34.8K | ﹤0.01% |
792
-178
| -18% | -$7.82K |
|
1319
Dine Brands
DIN
$364M
| $34.5K | ﹤0.01% |
+743
| New | +$34.5K |
|
1320
Akero Therapeutics
AKRO
$3.58B
| $34.5K | ﹤0.01% |
+1,365
| New | +$34.5K |
|
|
SAGE
1321
DELISTED
Sage Therapeutics
SAGE
| $34.2K | ﹤0.01% |
+1,826
| New | +$34.2K |
|
1322
Teladoc Health
TDOC
$1.38B
| $33.8K | ﹤0.01% |
2,240
+171
| +8% | +$2.58K |
|
1323
Ambarella
AMBA
$3.54B
| $33.7K | ﹤0.01% |
664
+476
| +253% | +$24.2K |
|
1324
Biomea Fusion
BMEA
$114M
| $33.7K | ﹤0.01% |
+2,254
| New | +$33.7K |
|
1325
Acadia Pharmaceuticals
ACAD
$4.26B
| $33.7K | ﹤0.01% |
+1,822
| New | +$33.7K |
|